The Myriad RBM KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.
Urine Biomarkers v. 2.0
|1. Beta-2-Microglobulin||2. Calbindin|
|3. Clusterin||4. Creatinine|
|5. Cystatin-C||6. Kidney Injury Molecule-1|
|7. Microalbumin||8. Neutrophil Gelatinase-Associated Lipocalin|
|9. Osteopontin||10. Vascular Endothelial Growth Factor|
Serum/Plasma Biomarkers v. 1.0
1 This assay did not meet performance specifications in EDTA-Plasma and results should be used for information purposes only.
2 This assay did not meet performance specifications in Serum and results should be used for information purposes only.
Intended for Research Use Only.
|Urine||Serum or plasma||Other fluids*|
|100 µL||50 µL||350 µL|